Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

US Executive Order on Advancing American Kidney Health

July 12, 2019
Download  full announcement Renalytix AI welcomes US Administration’s dedication to advancing American kidney health Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, welcomes the Executive Order signed by the President of the

FractalDx Positive Results Published in JASN

July 8, 2019
Download  full announcement Published data on blood diagnostic for subclinical acute kidney transplant rejection and potential to tailor immunosuppressive therapy Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces positive

US CPT® Code Granted for KidneyIntelX™

July 1, 2019
Download  full announcement CPT Code a key component for reimbursement from private medical insurance and Medicare Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that the American Medical Association (AMA) has granted

U.S. CPT® Code Granted for KidneyIntelX™

July 1, 2019
CPT Code a key component for reimbursement from private medical insurance and Medicare   NEW YORK, July 1, 2019 /PRNewswire/ --  Renalytix AI plc  (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that the American Medical

Positive results from FractalDx study published

June 7, 2019
Download  full announcement Demonstrates ability to predict early rejection in kidney transplant Supports successful development of a predictive blood test for transplant patients Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease,
Displaying 81 - 90 of 128